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detect lymph node (LN)
metastasis without using the
size criteria. This resulted in
the detection of metastases in
normal-size LNs and suspi-
cious LNs outside the
conventional CTV. Poten-
tially, these findings allow us
to individualize treatment
selection and enable image-
guided radiotherapy for
patients with PCa LN
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Open access undPurpose: To determine the clinical value of two novel molecular imaging techniques:
11C-choline positron emission tomography (PET)/computed tomography (CT) and
ferumoxtran-10 enhanced magnetic resonance imaging (magnetic resonance lymphography
[MRL]) for lymph node (LN) treatment in prostate cancer (PCa) patients. Therefore, we evalu-
ated the ability of PET/CT and MRL to assess the number, size, and location of LN metastases in
patients with primary or recurrent PCa.
Methods and Materials: A total of 29 patients underwent MRL and PET/CT for LN evaluation.
The MRL and PET/CT data were analyzed independently. The number, size, and location of the
LN metastases were determined. The location was described as within or outside the standard
clinical target volume for elective pelvic irradiation as defined by the Radiation Therapy
Oncology Group. Subsequently, the results from MRL and PET/CT were compared.
Results: Of the 738 LNs visible on MRL, 151 were positive in 23 of 29 patients. Of the 132 LNs
visible on PET/CT, 34 were positive in 13 of 29 patients. MRL detected significantly more posi-
tive LNs (p < 0.001) in more patients than PET/CT (p Z 0.002). The mean diameter of the
detected suspicious LNs on MRL was significantly smaller than those detected by PET/CT,
4.9 mm and 8.4 mm, respectively (p < 0.0001). In 14 (61%) of 23 patients, suspicious LNs were
found outside the clinical target volume with MRL and in 4 (31%) of 13 patients with PET/CT.
Conclusion: In patients with PCa, both molecular imaging techniques, MRL and 11C-choline
PET/CT, can detect LNs suspicious for metastasis, irrespective of the existing size and shape
criteria for CT and conventional magnetic resonance imaging. On MRL and PET/CT, 61%
and 31% of the suspicious LNs were located outside the conventional clinical target volume.Department of Radiology,
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Volume 84  Number 3  2012 Molecular imaging techniques: LN metastases in PCa 713Therefore, these techniques could help to individualize treatment selection and enable image-
guided radiotherapy for patients with PCa LN metastases.
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Open access under the Elsevier OA license.Table 1 Patient characteristics and demographics pertaining
to PET/CT and MRL imaging
Characteristics and demographics Value
Patients (n) 29
Age (y)
Mean  SD 63  9
Range 48e79
PET/CT and USPIO MRL performed (n)
Before local therapy 7
After radical prostatectomy with increasing
PSA level
9
After radical prostatectomy combined with HT 7
After HT 5
After HIFU combined with HT 1
Patients receiving HT (n) 13
PSA value at diagnosis (ng/mL)





Interval between PET/CT and USPIO MRL (d) 36  52
Abbreviations: CT Z computed tomography; HIFU Z high-
intensity ultrasound; HT Z hormonal therapy; MRL Z magnetic
resonance lymphography; PET Z positron emission tomography;
PSA Z prostate-specific antigen; USPIO Z ultra-small super-para-
magnetic iron-oxide nanoparticles.Introduction
Prophylactic whole pelvic radiotherapy (WPRT) is often given for
high-risk and unfavorable intermediate-risk prostate cancer (PCa)
patients, in addition to hormonal therapy. However, the outcome
has been variable. Two main reasons for this could be differences
in patient selection, variability in the a priori risk of lymph node
(LN) involvement, and variability in the radiation fields (1, 2). The
need for an accurate target volume for LN RT was recently
underlined by Ganswindt et al. (3), who presented an anatomic
atlas of prostate sentinel LNs. They found 66% of patients had
sentinel LNs outside the standard target volume used. The findings
of Ganswindt et al. (3) suggest that geographic miss is
a substantial problem in WPRT and that more accurate methods
for imaging LN metastases are needed. Also, the use of more
accurate imaging techniques could improve patient selection for
WPRT.
Equations and nomograms that predict the risk of LN
involvement for patient selection are based on the prostate-specific
antigen (PSA) value and Gleason grade. In the detection of local
recurrence, PSA kinetics can be useful; however, they have
limited value for predicting LN involvement (4). The nodal risk
formula overestimates LN involvement, leading to significant
overtreatment (5). Nomograms have to be used, because
morphologic imaging techniques, such as conventional magnetic
resonance imaging (MRI) or computed tomography (CT), are not
sufficiently sensitive nor sufficiently specific in the detection of
LN metastasis. A meta-analysis by Ho¨vels et al. (6) in 2008
showed a pooled sensitivity of 0.42 and 0.39 and a pooled spec-
ificity of 0.82 and 0.82 for CT and MRI, respectively. Invasive
surgical standard pelvic LN dissection also underestimates LN
involvement in high-risk and unfavorable intermediate-risk PCa
patients (1). A reason for underestimating LN metastases could be
that 40%e50% of the positive LNs are found outside the surgical
standard pelvic LN dissection field. Furthermore, sensitivity is
lacking for the standard cytopathologic evaluation, resulting in
a false-negative rate of 30%, mainly because of micrometastasis
(1). Thus, limited information is available about the correct
number, size, and location of metastatic LNs.
Molecular imaging techniques, such as ferumoxtran-
10eenhanced magnetic resonance lymphography (MRL) and
11C-choline PET/CT (PET/CT), with the ability to visualize
specific cell or tissue function, can potentially improve the accu-
racy for assessing the LN status.
Magnetic resonance lymphography is a molecular imaging
technique capable of separating normal functioning LN tissue
from LN tissue invaded by metastasis by labeling the macro-
phages in normal LNs with ferumoxtran-10. MRL does not rely on
the conventional size and shape criteria to detect LN metastases.
Several studies have indicated that the diagnostic performance of
MRL in pretreatment patients varies from 88% to 90% and 96% to
98% for sensitivity and specificity, respectively (7e9).11C-choline is a PET agent that is incorporated into tumor cells
after phosphorylation by choline kinase (10). PET/CT is an accurate
and sensitive imaging method for the staging of pelvic LNs (11).
The reported performance of PET/CT for LN metastasis detection
varies from 60% to 64% for sensitivity and 90% to 98% for spec-
ificity on a patient-by-patient analysis, respectively (12, 13).
Because these molecular imaging modalities appear to be
more accurate for the detection of LN metastases than conven-
tional imaging, they might have a potential role in the workup of
PCa patients, who might be candidates for WPRT. Thus, the aim
of the present study was to evaluate the findings of MRL and
PET/CT within the same patient group in terms of the number,
size, and location of positive LNs to evaluate their potential




A group of 29 patients with either primary PCa or recurrent
disease, who were referred for MRL at our institution in 2005 to
Fig. 1. Post-treatment patient. On both positron emission tomography/computed tomography (PET/CT) (A) and magnetic resonance
lymphography (MRL) (B), 9-mm positive lymph node (LN) (arrow) detected in right internal iliac region. MRL, however, also demon-
strated high-signal intensity 4-mm suspicious LN in left common iliac region (D, arrow), which was negative on PET/CT (C).
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institution were included. Of the 29 patients, 22 presented with
recurrent disease and 7 had been referred before their initial
treatment. All patients gave informed consent for the intravenous
injection of the LN contrast and the use of the obtained data for
research purposes. The patient characteristics and demographics
are listed in Table 1.Imaging and interpretation
The 29 PET/CT examinations were performed at four different
institutions using an identical integrated PET/CT system (Siemens
Healthcare, Erlangen Germany). All PET/CT Digital Imaging and
Communications in Medicine images were reconstructed in the
axial, coronal, and sagittal views and corrected for attenuation.
Two experienced nuclear medicine specialists (S.N.R., with 18
years’ experience, and C.S., with 2 years’ experience) qualita-
tively reviewed the images retrospectively to anatomically localize
the sites of pathologic 11C-choline uptake. LNs with increased
tracer uptake were considered suspicious for metastatic spread,
and LNs without detectable tracer uptake were considered
nonsuspicious.Magnetic resonance lymphography was performed at a field
strength of 1.5 Tesla (2 of 29) and 3.0 Tesla (27 of 29) using
a pelvic phased array coil (Sonata/Symphony and Trio, Siemens,
Erlangen, Germany). Two-dimensional magnetic resonance
images were acquired of the pelvis, extending from the renal
artery to the pubic bone 24 hours after the intravenous drip
infusion of ferumoxtran-10 (2.6 mg ferritin/kg); 20e35-nm
particle size (Guerbet, Paris, France), as described by Harisinghani
et al. (7) and Heesakkers et al. (8). All MRL images were
analyzed by 2 experienced uroradiologists (J.O.B. and S.T., with
11 and 2 years’ experience for evaluating MRL, respectively).
A LN was considered suspicious for metastasis if the entire LN or
a focal area did not show a low signal on the ferumoxtran-
10esensitive images. A LN was considered normal if it showed
a homogeneous low signal.
The size of the positive LNs on both modalities was deter-
mined. Their location was registered in relation to the clinical
target volume (CTV) for elective pelvic RT as defined by the
Radiation Therapy Oncology Group (14) by 2 independent
researchers (A.S.F. and H.J.M.M.).
The PET/CT and MRL images were evaluated by the imaging
specialists who were unaware of the outcomes from the other
modality and independent of each other.
Table 2 Node detection and characteristics for MRL and PET/CT
Variable MRL PET/CT p




Nodal size range (mm) 2e20 4e19
Positive nodes (n) 151 (n Z 23 patients) 34 (n Z 13 patients) 0.002y
Short diameter (mm) <0.0001*
Mean 4.9 8.4
Range 2e20 4e19
Positive node cutoff Z 7 mm
<7 125 12
7 26 22
Negative nodes (n) 587 98
Abbreviations: MRL Z magnetic resonance lymphography; PET Z positron emission tomography; CT Z computed tomography.
* Paired t test.
y McNemar test.
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The number, size, and location of the positive LNs using PET/CT
and MRL were compared and correlated by a third independent
radiologist (W.M.L.L.G.D.). The outcome was evaluated on
a patient and node analysis level. As a cutoff level for diameter
analysis, we used 7 mm, the minimal short-axis diameter for
malignant LN on plain MRI (15). For statistical analysis, the
paired t test was used: (1) to quantify the discordance between the
number of suspicious LNs found on PET/CT and MRL, and (2) to
evaluate the discordance between the axial diameter of the
suspicious LNs found on PET/CT and MRL. To evaluate the
discordance at the patient level, the McNemar test was performed.
The analyses were performed using Statistical Package for Social
Sciences, version 16.0, for Windows (SPSS, Chicago, IL).
Results
On MRL, 738 LNs were visible, of which 151 were suspicious for
metastasis in 23 of 29 patients. On PET/CT, 132 LNs were visible,
with 34 suspicious for metastasis in 13 of 29 patients. Positive
LNs on both MRL and PET/CT are shown in Fig. 1A,B, with LNsFig. 2. Overview of axial lymph node diameter of positive lymph no
axial diameter on magnetic resonance lymphography; PET/CT Z num
positron emission tomography/computed tomography.positive only on MRL are shown in Fig. 1C,D. Differences
in the number of positive LNs (p < 0.0001) and positive patients
(p Z 0.002) were significant (Table 2).
The mean diameter of detected positive LNs on MRL and PET/
CTwas significantly different at 4.9 mm and 8.4 mm, respectively
(p < 0.001; Table 2). Figure 2 illustrates the size distribution of
the positive LNs.
Magnetic resonance lymphography detected positive LNs in 10
of 29 patients with initial negative PET/CT findings and thus
changed the outcome of LN assessment from normal to positive.
Of these 10 patients, 3 presented before their initial treatment.
In these 10 patients, the all positive LNs were <7 mm (2 mm in 2,
3 mm in 14, 4 mm in 18, 5 mm in 7, and 6 mm in 5; Table 2 and
Fig. 2). In the 13 of 29 patients with positive findings on both
MRL and PET/CT, MRL detected 71 more positive LNs than
PET/CT. All 71 LNs were <7 mm (2 mm in 13, 3 mm in 20, 4 mm
in 19, 5 mm in 13, and 6 mm in 6; Tables 2 and 3).
On MRL, 125 of 151 positive LNs were <7 mm and only 26
were 7 mm. On PET/CT, 12 of 34 positive LNs were <7 mm
and 22 were 7 mm (Table 2 and Fig. 2).
The MRL and PET/CT findings showed 67 of 151 and 10 of 31
positive LNs in 14 (61%) of 23 and 4 (31%) of 13 patients outside
the CTV, respectively (Figs. 1D and 3 and Table 3).des. MRL Z number of found lymph nodes with corresponding
ber of found lymph nodes with corresponding axial diameter on
Table 3 Node detection in individual patients
Pt. No.
LN MRL LN PET/CT
Negative Positive Positive outside CTV Negative Positive Positive outside CTV
1 P 16 0 3 0
2 R 31 1 0 0
3 R 32 2 3 0
4 R 9 5 1 3 1
5 R 13 5 2 5 0
6 R 22 1 1 2
7 P 33 0 7 0
8 R 32 1 0 1
9 R 1 3 3 0 1 1
10 R 26 1 1 0
11 R 16 0 3 0
12 P 9 5 1 1 0
13 R 70 6 7 0
14 P 13 4 4 0
15 R 9 11 1 3 5 1
16 R 0 3 1 0 1
17 R 13 18 9 0 9 4
18 R 12 10 8 4 0
19 R 15 0 2 0
20 R 11 9 7 3 1
21 P 26 4 1 0
22 P 22 23 8 6 3
23 R 25 16 12 13 3
24 R 31 8 2 3 2
25 P 17 0 3 0
26 R 41 0 3 0
27 R 5 4 4 5 4 4
28 R 0 3 0 1
29 R 30 8 8 8 0
Abbreviations: PZ before initial treatment; RZ recurrent disease, LN MRLZ number of lymph nodes found on magnetic resonance lymphography;
LN PET Z number of lymph nodes found on positron emission tomography/computed tomography.
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metastases in 1 patient. MRL showed no relevant additional
findings.
Discussion
As molecular imaging techniques, both PET/CT and MRL can
detect LNs suspicious for metastasis without using the size criteria
and thus allows the detection of metastasis in small normal size
LN (<7 mm) on conventional MRI and CT.
The present study showed that more positive LNs were
detected with MRL than with PET/CT (p < 0.0001). The positive
LNs on MRL were smaller (p < 0.0001), and positive LNs were
detected in more patients (pZ 0.002). 11C-choline is a functional
technique that requires a minimal amount of tracer in viable
malignant tissue. MRL labels normal macrophages in the LNs.
Thus, it does not depend on the functional activity of cancer in the
LNs themselves. Furthermore, MRL has greater spatial resolution.
These differences explain why more and smaller positive LNs can
be detected with MRL. Harisinghani et al. (7) reported that with
MRL, 30% of metastases found in LNs are <5 mm and in 70% are
<10 mm. The detection rate in that study was slightly greater (125
of 151; 83% <7 mm). This minimal difference can be explainedby the predominantly greater field strength used in that study. A
greater field strength has been reported to improve the visibility of
small LNs on MRL (16). On PET/CT, the mean diameter of
positive LNs was 8.4 mm and varied from 4 to 19 mm. This agrees
with the reported data, in which the mean diameter of missed
(false-negative) LN metastasis on 11C-choline PET/CT varied
from 4 to 6 mm (12, 13). The mean number of detected LNs on
PET/CT in the published data ranged from 1 to 6 LNs and 0.2 to 2
LN metastasis/patient (11, 12), in agreement with our findings.
PET/CT and MRL detected 22 and 26 positive LNs that were 7
mm, respectively, and therefore the findings substantially agree
(Fig. 2 and Table 2). For LNs with an axial diameter of 6 mm,
however, the difference between the two modalities was signifi-
cant. Thus, the difference between these two molecular imaging
techniques lies in the ability of MRL to detect LNs of 6 mm.
Histologic confirmation of the positive LNs was not possible in
our group as presented. The lack of histologic confirmation was
a limitation of our study. However, our results are in line with in
the previously cited data (7e9, 11e13, 16) and the expectations
based on the differences in the modalities.
Both PET/CT and MRL could have a role in the workup of PCa
patients. For primary PCa, pelvic LN dissection can be omitted if
the a priori risk of LN involvement is <5% (17). Based on the
reported high sensitivity (88%e90%) and negative predictive
Fig. 3. Post-treatment patient with positive lymph nodes outside clinical target volume. Positron emission tomography/computed
tomography (A) detected one and magnetic resonance lymphography (B) detected multiple positive para-aortal lymph nodes outside
clinical target volume (arrows). These lymph nodes showed no signal drop on ferumoxtran-10esensitive images and were thus white.
Volume 84  Number 3  2012 Molecular imaging techniques: LN metastases in PCa 717value (97%e98%) of MRL, this is possible if the MRL findings
are negative (7, 8). This was the case for 3 of 7 patients. Thus, 4 of
the 7 patients were upstaged. With the use of PET/CT, it is less
safe to omit pelvic LN dissection, because the sensitivity
(41%e64%) and negative predictive value (72%e97%) in the
published data on a nodal basis are too low to ensure a sufficiently
low a priori risk (12, 13). Only 1 of 7 patients had LN metastasis
on PET/CT (and MRL as well). Two of the patients who were only
positive on MRL had their LNs outside the CTV (Table 3).
In the workup of recurrent PCa patients, more accurate
imaging methods for determining LN status before local salvage
therapy might be even more important. Pelvic LN dissection is
usually not performed in patients with recurrent disease, and no
nomograms are available to predict the risk of LN involvement. In
the present study, 22 of 29 patients developed a PSA relapse after
the initial treatment (Table 3). Of these 22 patients, 12 had positive
LNs on both MRL and PET/CT, and 7 had positive LNs on MRL
only. Of the patients with recurrence, 4 and 8 had positive LNs
outside the CTV on PET/CT and MRL and on MRL alone,
respectively (Table 3 and Fig. 3).
When no LN or distant metastases are present, a PSA relapse is
likely to be caused by local recurrence only and, thus, local
therapy is indicated. However, if LN metastases are present,
usually systemic hormonal therapy without or with RT is given.
The latter group seems to have better survival (18).
Magnetic resonance lymphography detected positive LNs
outside the CTV in 14 (61%) of 23 of all positive patients and in
12 (63%) of 19 positive patients with PSA relapse. Preventing
geographic miss by knowledge of the LN metastasis location
could improve target volume definition and therefore the
outcomes of WPRT. Furthermore, recent research toward treating
known positive LNs has been encouraging. Recent research
showing MRL-guided boost RT to positive LNs to be feasible hasbeen encouraging (19). MRL-guided hypofractionated intensity-
modulated RT in patients with known positive LNs seems to be
safe and has shown promising results in follow-up (20).
Conclusion
In patients with PCa, both molecular imaging techniques, MRL
and PET/CT, can detect LNs suspicious for metastasis, irre-
spective of the existing size and shape criteria for CT and
conventional MRI. However, MRL seems superior to PET/CT in
detecting positive LNs <7 mm. On MRL and PET/CT, positive
LNs were located outside the conventional CTV in 14 (61%) of 23
and 4 (31%) of 13 positive patients, respectively. Thus, MRL and
PET/CT might help to individualize treatment selection and
enable image-guided RT.References
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